High materiality7/10
Revolution Medicines price target raised to $265 from $220 at UBS
Why it may matterVerify against the original reporting
Target upgrade indicates meaningful upside; bullish setup.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
UBS raises Revolution Medicines target to $265 from $220; current price $221.15.
- Target: $265
- Current price: $221.15
- Firm: UBS
Key facts
- 01
Target: $265
- 02
Posted price: $221.15
- 03
Analyst firm: UBS
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.